BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Now Covered by Analysts at JPMorgan Chase & Co.

Stock analysts at JPMorgan Chase & Co. began coverage on shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) in a report issued on Wednesday,Benzinga reports. The brokerage set an “overweight” rating and a $27.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 225.69% from the company’s current price.

BBOT has been the topic of a number of other research reports. Canaccord Genuity Group assumed coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $23.00 price target on the stock. Oppenheimer started coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They set an “outperform” rating and a $22.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th. UBS Group lowered shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a report on Wednesday. Finally, Wall Street Zen cut BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.80.

BridgeBio Oncology Therapeutics Price Performance

BridgeBio Oncology Therapeutics stock opened at $8.29 on Wednesday. The stock has a fifty day simple moving average of $8.10. BridgeBio Oncology Therapeutics has a twelve month low of $7.00 and a twelve month high of $14.87. The company has a market capitalization of $664.11 million, a P/E ratio of -4.04 and a beta of 0.39.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. As a group, analysts predict that BridgeBio Oncology Therapeutics will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC bought a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $63,000. Persistent Asset Partners Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter worth approximately $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $144,000. Quadrature Capital Ltd bought a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $162,000. Finally, BIT Capital GmbH purchased a new position in BridgeBio Oncology Therapeutics during the fourth quarter valued at $313,000. 54.89% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.